{
    "clinical_study": {
        "@rank": "65710", 
        "brief_summary": {
            "textblock": "RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for\n      cancer cell growth.\n\n      PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating women who have\n      metastatic breast cancer."
        }, 
        "brief_title": "PS-341 in Treating Women With Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the objective tumor response in women with metastatic breast cancer treated\n           with bortezomib.\n\n        -  Determine the toxic effects of this drug in these patients.\n\n        -  Determine the progression-free survival in patients treated with this drug.\n\n      OUTLINE: Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Treatment\n      repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 6-24\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed adenocarcinoma of the breast\n\n               -  Metastatic disease\n\n          -  At least 1 unidimensionally measurable lesion\n\n               -  At least 20 mm by conventional techniques OR\n\n               -  At least 10 mm by spiral CT scan\n\n          -  Previously treated with 1 prior chemotherapy regimen (with or without trastuzumab\n             [Herceptin]) for metastatic disease\n\n               -  Relapse during or within 6 months after completion of adjuvant chemotherapy\n                  considered treatment failure\n\n          -  No known brain metastases\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count greater than 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  SGOT/SGPT no greater than 2.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine normal OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Other:\n\n          -  No uncontrolled concurrent illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study\n\n          -  No prior allergic reaction attributed to compounds of similar chemical or biological\n             composition to bortezomib\n\n          -  No other prior malignancy within the past 5 years unless curatively treated and\n             disease free\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  See Disease Characteristics\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n        Endocrine therapy:\n\n          -  Prior hormonal therapy for metastatic disease allowed\n\n          -  At least 4 weeks since prior hormonal therapy and recovered\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  Prior adjuvant therapy allowed\n\n          -  At least 4 weeks since prior investigational drugs and recovered\n\n          -  No other concurrent investigational or commercial agents or therapies for breast\n             cancer\n\n          -  No concurrent combination antiretroviral therapy for HIV"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 4, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00028639", 
            "org_study_id": "NCI 00B11", 
            "secondary_id": [
                "NU-NCI00B11", 
                "NCI-1862"
            ]
        }, 
        "intervention": {
            "intervention_name": "bortezomib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "July 1, 2011", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611-3013"
                }, 
                "name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "Robert H. Lurie Cancer Center", 
            "last_name": "William J. Gradishar, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00028639"
        }, 
        "responsible_party": {
            "name_title": "William Gradishar, MD", 
            "organization": "Northwestern University"
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2011"
    }, 
    "geocoordinates": {
        "Robert H. Lurie Comprehensive Cancer Center, Northwestern University": "41.878 -87.63"
    }
}